Print  |  Font Size Change Font Size
Search naabt.org  

The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv®4, Bunavail™5, Probuphine®6) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2

TreatmentMatch.org - Patient/Physician Matching System: What is it?

The free-of-charge matching system is a confidential way for physicians in an office-based practice to find, screen and contact patients seeking buprenorphine treatment for opioid dependence.
More

How do I get started?

Complete the one-time confidential registration.
 Register
 
Already registered? Click here to login now.
   

Then what?

  1. You will receive an alert email as soon as a patient in your area registers.

  2. Log in to view patient profile and contact them if they are appropriate for your practice.
Get Started

Common Concerns


Do patients see my email address? - No.

Will I be placed on any public list? - Only if you opt to.

Can I opt out at any time? - Yes.

Is this different from the SAMHSA locator? - Yes.

Can I decide if I get emails or not? - Yes.

More Frequently Asked Questions

For More Information:



Detailed information and instructions.

A demonstration version to try.

Live Map of patients seeking treatment - right NOW

The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
  5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
  6. Probuphine FDA approved 5/26/2016 - FDA Probuphine press release